See more : H & M Hennes & Mauritz AB (publ) (HNNMY) Income Statement Analysis – Financial Results
Complete financial analysis of COMPASS Pathways plc (CMPS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of COMPASS Pathways plc, a leading company in the Medical – Care Facilities industry within the Healthcare sector.
You may be interested
- Yamana Gold Inc. (RNY.DE) Income Statement Analysis – Financial Results
- European Reliance General Insurance Company S.A. (ERPRF) Income Statement Analysis – Financial Results
- Hargreaves Services Plc (HGRVF) Income Statement Analysis – Financial Results
- Ningbo Energy Group Co.,Ltd. (600982.SS) Income Statement Analysis – Financial Results
- First Hi-tec Enterprise Co., Ltd. (5439.TWO) Income Statement Analysis – Financial Results
COMPASS Pathways plc (CMPS)
About COMPASS Pathways plc
COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that has completed Phase IIb clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 242.94K | 329.80K | 174.98K | 112.00K | 63.00K | 0.00 |
| Gross Profit | -242.94K | -329.80K | -174.98K | -112.00K | -63.00K | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 87.52M | 65.05M | 44.03M | 23.37M | 12.56M | 8.92M |
| General & Administrative | 49.40M | 45.35M | 39.19M | 28.03M | 8.62M | 3.59M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 49.40M | 45.35M | 39.19M | 28.03M | 8.62M | 3.59M |
| Other Expenses | 0.00 | -14.42M | -9.65M | -4.25M | -2.73M | -2.68M |
| Operating Expenses | 136.92M | 95.98M | 73.57M | 47.15M | 18.45M | 10.54M |
| Cost & Expenses | 136.92M | 95.98M | 73.57M | 47.15M | 18.45M | 10.54M |
| Interest Income | 0.00 | 0.00 | 40.00 | 319.00 | 73.00 | 0.00 |
| Interest Expense | 2.21M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 242.94K | 329.80K | 174.98K | 112.00K | 63.00K | 22.00K |
| EBITDA | -123.80M | -110.40M | -83.22M | -47.04M | -18.39M | -10.52M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -136.92M | -110.40M | -83.22M | -51.39M | -21.18M | -12.50M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 19.24M | 19.31M | 11.68M | -8.91M | 1.58M | -716.00K |
| Income Before Tax | -117.68M | -91.10M | -71.54M | -60.30M | -19.60M | -13.22M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 780.00K | 408.00K | 199.00K | 32.00K | 15.00K | -716.00K |
| Net Income | -118.46M | -91.51M | -71.74M | -60.33M | -19.61M | -13.22M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -2.32 | -2.16 | -1.79 | -1.68 | -0.90 | 0.00 |
| EPS Diluted | -2.32 | -2.16 | -1.79 | -1.68 | -0.90 | 0.00 |
| Weighted Avg Shares Out | 51.03M | 42.44M | 40.00M | 35.93M | 21.72M | 17.26B |
| Weighted Avg Shares Out (Dil) | 51.03M | 42.44M | 40.00M | 35.93M | 21.72M | 17.26B |
Compass Pathways Announces Fourth Quarter 2023 Financial Results and Business Highlights
LONDON, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results for the fourth quarter 2023 and provided an...
Penny Power Players: 3 Stocks to Watch in the Microcap Arena
There are some great microcap stocks for investors to scoop up this month. The broader indices, such as the S&P 500 and the Nasdaq, are showing signs of both strength and weakness, but I believe that there's still a lot...
Compass Pathways to participate in upcoming TD Cowen investor conference
LONDON, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will participate in a panel discussion at the TD Cowen...
Compass Pathways to announce fourth quarter and year-end 2023 financial results on February 29, 2024
LONDON, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the fourth quarter and year-end...
Wall Street Says Compass Pathways Could Rise 307%. Here's How It Could Actually Happen.
Compass will report some critical clinical trial data this year. One of its peers could soon see its first drug approved.
Compass Pathways: Psilocybin Developer A Potentially Intriguing, Contrarian Play
Compass Pathways plc, a biotech company based in London, is developing a psilocybin-based therapy for CNS disorders. The company's shares declined by over 80% in 2022 due to safety concerns and regulatory hurdles.
Compass Pathways to participate in upcoming Oppenheimer investor conference
LONDON, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will hold a fireside chat at the Oppenheimer 34th Annual...
test
test
Compass Pathways enters into research collaboration agreement with Hackensack Meridian Health to develop optimal clinical model for investigational COMP360 psilocybin treatment, if FDA-approved
LONDON, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, and Hackensack Meridian Health (“HMH”), a leading not-for-profit health care organization and the...
Therapy's New Frontier: 3 Psychedelic Stocks for the Mental Health Revolution
Though psychedelic therapies and related psychedelic stocks have fallen out of favor recently, there's still tremendous research and insight happening beneath the surface. Even Elon Musk uses ketamine as a depression therapeutic.
Source: https://incomestatements.info
Category: Stock Reports